Yuan Meng, Chen Xiaobing, Sun Yitang, Jiang Li, Xia Zhongni, Ye Kaixiong, Jiang Hong, Yang Bo, Ying Meidan, Cao Ji, He Qiaojun
Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Department of Genetics, University of Georgia, Athens, GA 30602, USA.
Acta Pharm Sin B. 2020 Aug;10(8):1426-1439. doi: 10.1016/j.apsb.2020.03.008. Epub 2020 Apr 19.
The membrane protein claudin-3 (CLDN3) is critical for the formation and maintenance of tight junction and its high expression has been implicated in dictating malignant progression in various cancers. However, the post-translational modification of CLDN3 and its biological function remains poorly understood. Here, we report that CLDN3 is positively correlated with ovarian cancer progression both and Of interest, CLDN3 undergoes -palmitoylation on three juxtamembrane cysteine residues, which contribute to the accurate plasma membrane localization and protein stability of CLDN3 Moreover, the deprivation of -palmitoylation in CLDN3 significantly abolishes its tumorigenic promotion effect in ovarian cancer cells. By utilizing the co-immunoprecipitation assay, we further identify ZDHHC12 as a CLDN3-targating palmitoyltransferase from 23 ZDHHC family proteins. Furthermore, the knockdown of ZDHHC12 also significantly inhibits CLDN3 accurate membrane localization, protein stability and ovarian cancer cells tumorigenesis Thus, our work reveals -palmitoylation as a novel regulatory mechanism that modulates CLDN3 function, which implies that targeting ZDHHC12-mediated CLDN3 -palmitoylation might be a potential strategy for ovarian cancer therapy.
膜蛋白claudin-3(CLDN3)对于紧密连接的形成和维持至关重要,其高表达与多种癌症的恶性进展有关。然而,CLDN3的翻译后修饰及其生物学功能仍知之甚少。在此,我们报告CLDN3与卵巢癌进展在[此处原文缺失相关内容]均呈正相关。有趣的是,CLDN3在三个近膜半胱氨酸残基上发生棕榈酰化,这有助于CLDN3准确的质膜定位和蛋白质稳定性。此外,CLDN3中棕榈酰化的缺失显著消除了其在卵巢癌细胞中的致瘤促进作用。通过免疫共沉淀实验,我们从23种ZDHHC家族蛋白中进一步鉴定出ZDHHC12作为一种靶向CLDN3的棕榈酰转移酶。此外,敲低ZDHHC12也显著抑制CLDN3的准确膜定位、蛋白质稳定性以及卵巢癌细胞的肿瘤发生。因此,我们的研究揭示棕榈酰化是一种调节CLDN3功能的新型调控机制,这意味着靶向ZDHHC12介导的CLDN3棕榈酰化可能是卵巢癌治疗的一种潜在策略。
Acta Pharm Sin B. 2020-8
J Egypt Natl Canc Inst. 2022-6-6
Cancer Biol Ther. 2007-11
Proc Natl Acad Sci U S A. 2009-3-3
J Hematol Oncol. 2025-9-1
Innovation (Camb). 2025-4-29
Cell Death Discov. 2025-7-18
Acta Pharmacol Sin. 2025-7-17
Int J Cardiol Heart Vasc. 2025-4-4
Front Oncol. 2025-2-24
Acta Pharm Sin B. 2020-2
Acta Pharm Sin B. 2019-9
Proc Natl Acad Sci U S A. 2019-2-28
EMBO Rep. 2018-9-19
Crit Rev Biochem Mol Biol. 2018-7-12